In a decision that underscores the complexities of legal obligations in merger advisory roles, the United States Court of Appeals for the Second Circuit upheld the dismissal of a lawsuit filed by a Myovant Sciences Ltd. investor. The appeal sought to revive allegations of a conflict of interest against the law firm Skadden, Arps, Slate, Meagher & Flom LLP, which advised Myovant during its acquisition by Sumitovant Biopharma Ltd.
The crux of the investor’s argument was an alleged necessity for Skadden to disclose potential conflicts of interest arising from its role in the transaction. The complaint was that Skadden’s advisory position entailed conflicts due to its previous representation of entities linked to the acquiring company. However, the Circuit court found these allegations insufficient, as they failed to establish a direct relationship between Skadden and Sumitovant or its parent company. Rather, the ties described in the complaint were deemed too attenuated, involving multiple layers of corporate associations that did not mandate further disclosure.
The appeal decision by the Second Circuit confirms the assessment of the lower court, reinforcing the threshold for material conflict disclosures in corporate mergers and acquisitions. Lawyers and corporate advisors may view this decision as a clarifying instance regarding what constitutes a sufficiently direct relationship necessitating conflict-of-interest disclosure. For further reading, the full decision details can be accessed through Bloomberg Law’s extensive coverage of the case.